Published in Medical Letter on the CDC and FDA, March 6th, 2000
"Invasive group A streptococcal (GAS) infections are a cause of serious morbidity and high mortality. There is a need for a simple, effective antimicrobial regimen that could be used to prevent invasive GAS disease in high risk situations," according to J.Y. Morita and colleagues at the U.S. Centers for Disease Control and Prevention ("Impact of azithromycin on oropharyngeal carriage of Group A Streptococcus and nasopharyngeal carriage of macrolide-resistant Streptococcus pneumoniae," Pediatric Infectious Disease...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.